Literature DB >> 8721333

Role of tissue inhibitors of metalloproteinase in diabetic nephropathy.

M Kanauchi1, H Nishioka, Y Nakashima, T Hashimoto, K Dohi.   

Abstract

We evaluated the role of tissue inhibitors of metalloproteinase-1 (TIMP-1) in patients with diabetic nephropathy by comparing the serum and urine TIMP-1 levels with those of renal biopsy specimens. A total of 35 diabetic patients were divided into four groups, D0, DI, DII and DIII-IV, according to the severity of diffuse glomerular lesions using Gellman's criteria. Using serum and 24-hour urine specimens, TIMP-1 was measured by a sandwich enzyme immunoassay. Serum and urinary TIMP-1 showed significant increases in association with the progress of glomerular diffuse lesions. There was no correlation between serum TIMP-1 and serum creatinine, creatinine clearance, serum and urinary beta 2-microglobulin, urinary NAG, HbA1c, or urinary TIMP-1. There was a significant correlation between urinary TIMP-1 and urinary albumin, and was a significant correlation between urinary TIMP-1 and urinary NAG. We conclude that TIMP-1 has a potential role in the regulation of glomerular matrix accumulation in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721333

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  7 in total

Review 1.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

2.  The association between levels of tissue inhibitor of metalloproteinase-1 with acute heart failure and left ventricular dysfunction in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention.

Authors:  Monika Pavkova Goldbergova; Jiri Parenica; Jiri Jarkovsky; Petr Kala; Martin Poloczek; Jan Manousek; Krystyna Kluz; Lenka Kubkova; Simona Littnerova; Martin Tesak; Ondrej Toman; Nikolas Pavek; Zdenka Cermakova; Josef Tomandl; Anna Vasku; Jindrich Spinar
Journal:  Genet Test Mol Biomarkers       Date:  2012-09-12

3.  Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.

Authors:  Tetsuya Endo; Kimimasa Nakabayashi; Makiho Sekiuchi; Tadahide Kuroda; Akinori Soejima; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

Review 4.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 5.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

6.  Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.

Authors:  Masako Furukawa; Tomohito Gohda; Shinji Hagiwara; Mitsuo Tanimoto; Satoshi Horikoshi; Kazuhiko Funabiki; Yasuhiko Tomino
Journal:  Int J Nephrol       Date:  2013-06-02

Review 7.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.